Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Able to understand and comply with all study procedures including availability for all study visits and follow up surveys within 6 months following study enrollment.~* DEERS eligible beneficiaries eligible for influenza vaccination and able to give informed consent.~* Age 18-49~  * Patients presenting to travel clinic with no exclusion criteria;~ * Household contacts and out-of-home caretakers of infants from 6-23 months of age;~ * Hospital and/or employees providing service to the public who are not eligible for the post-October 5th recommendations for priority immunization;~ * DOD employees eligible for influenza vaccination prior to October 5th but excluded in the post October 5th guidelines;~ * People living in dormitories or under other crowded conditions, to prevent outbreaks;~* Ages 50-64 years of age who are not eligible for the post-October 5th recommendations for priority immunization and with no standard of care contraindications to vaccination.~* Eligible in the Department of Defense for influenza vaccination~Exclusion Criteria:~* all children aged \< 18 years (includes children aged 6 months-18 years on chronic aspirin therapy);~* adults aged \>65 years;~* persons aged 2-64 years with underlying chronic medical conditions:~  * includes persons with chronic cardiac or pulmonary disease, diabetes mellitus, hemoglobinopathy, or immunosuppressive illness;~ * any acute or chronic condition that, in the opinion of the investigator, would render vaccination unsafe or interfere with the evaluation of response.~* use of experimental vaccines or medications within 30 days of study entry;~* receipt of parenteral immunoglobulin within 60 days of study entry;~* all women who will be pregnant during the influenza season;~* residents of nursing homes and long-term care facilities;~* health-care workers involved in direct patient care and included in DOD priority 1; and;~* military recruits;~* out-of-home caregivers and household contacts of children aged \<6 months.~* Anyone with clinical contraindications for receiving the inactivated influenza vaccine such as a history of severe allergic reaction to prior influenza vaccinations, severe allergy to egg and/or egg proteins and gelatin.~* DOD Priority 1: Deployed or deploying (with orders) service members and others designated as critical to national defense.~* DOD Priority 2: Medically high risk in accordance with ACIP guidelines (includes health-care workers with direct patient contact)~* Any acute or chronic condition that, in the opinion of the investigator or her provider designee would render vaccination unsafe or interfere with the evaluation of the response.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Male, Age 18 -49, Full Dose (Type: EXPERIMENTAL): 0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
- Male, Age 50 -64, Half Dose (Type: EXPERIMENTAL): 0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
- Female, Age 18 - 49, Full Dose (Type: EXPERIMENTAL): 0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
- Female, Age 18 - 49, Half Dose (Type: EXPERIMENTAL): 0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
- Male, Age 18 - 49, Half Dose (Type: EXPERIMENTAL): 0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
- Male, Age 50 -64, Full Dose (Type: EXPERIMENTAL): 0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
- Female, Age 50 -64, Full Dose (Type: EXPERIMENTAL): 0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
- Female, Age 50 -64, Half Dose (Type: EXPERIMENTAL): 0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete